Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.
Key PointsBoth companies are giants in diabetes and obesity treatments...
Nasdaq News: Markets
More News
NVO Stock Slumps After Late-Stage Trial Fails Primary Goal – Retail Says ‘Current Revenue Drivers’ Still Intact
Novo’s Phase 3 trial showed that investigational drug Ziltivekimab did not reduce major adverse cardiovascular events compared with the placebo
Stocktwits
HIMS Stock Eyes 4-Week Losing Streak: Legal Woes Fuel ‘Very High’ Uncertainty As Analyst Sticks To ‘No Moat’ Call
Morningstar maintained a ‘No Moat’ view, citing low telehealth barriers and offerings rivals can replicate “with relative ease.”
Stocktwits
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t
Viking expects oral VK2735 Phase 3 studies to begin in Q4 and believes the pill could become the first oral dual GLP-1 agonist to reach the market.
Stocktwits
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?
Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.
Zacks
Why shareholders are suing Novo Nordisk over next-generation weight-loss drug
Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap...
CNBC: Healthcare
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients
Key PointsAmgen wants a slice of the weight loss drug market...
Nasdaq News: Markets
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing
Novo Nordisk (NVO) reached $50.96 at the closing of the latest trading day, reflecting a +2.6% change compared to its last close.
Zacks
Where Will Novo Nordisk Stock Be in 3 Years?
Key PointsNovo Nordisk remains a step behind Eli Lilly in the weight loss drug market...
Nasdaq News: Markets
Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?
Key PointsEli Lilly's ads don't account for a new, higher dose of Novo Nordisk's Wegovy...